The cardiovascular actions of ellipticine.
D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000470:Alkaloids / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects; D002227:Carbazoles / Q000008:administration & dosage / Q000494:pharmacology*; D002319:Cardiovascular System / Q000187:drug effects*; D002395:Catecholamines / Q000502:physiology; D003864:Depression, Chemical; D004285:Dogs; D004562:Electrocardiography; D000882:Haplorhini; D006321:Heart / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D066298:In Vitro Techniques; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects; D010477:Perfusion; D011433:Propranolol / Q000494:pharmacology; D011941:Receptors, Adrenergic; D012110:Reserpine / Q000494:pharmacology; D012119:Respiration / Q000187:drug effects; D013268:Stimulation, Chemical; D016276:Ventricular Function
D000318:Adrenergic beta-Agonists; D000470:Alkaloids; D000970:Antineoplastic Agents; D002227:Carbazoles; D002395:Catecholamines; D011941:Receptors, Adrenergic; D012110:Reserpine; D011433:Propranolol